PD-L1 expression in lung adenocarcinoma harboring &ITEGFR&IT mutations or &ITALK&IT rearrangements
PD-L1 expression in lung adenocarcinoma harboring &ITEGFR&IT mutations or &ITALK&IT rearrangements
复制标题
DOI：
10.1016/j.lungcan.2018.01.024
复制
发表时间：
2018-04-01
期刊：
影响因子：
5.3
通讯作者：
Okamoto, Isamu
中科院分区：
文献类型：
--
作者：
Yoneshima, Yasuto;Ijichi, Kayo;Okamoto, Isamu
目的：程序性细胞死亡配体 1 (PD-L1) 的表达与非小细胞肺癌 (NSCLC) 中程序性细胞死亡-1 (PD-1) 通路阻断的临床结果相关。 PD-L1 IHC 22C3 pharmDx 测定是帕博利珠单抗治疗的唯一伴随诊断，已显示大约 30% 的 NSCLC 表达高水平 PD-L1。然而，具有已知驱动癌基因的 NSCLC 中 PD-L1 高表达的频率仍不清楚。 材料和方法：我们通过 22C3 检测回顾性评估了 80 名肺腺癌患者的肿瘤组织中 PD-L1 的表达，其中 71 名有 EGFR 突变，9 名有 ALK 重排，所有这些患者都接受了相应的酪氨酸激酶抑制剂 (TKI) 治疗。 结果：在分析的 80 个肿瘤中，26 个(32.5%) 的 PD-L1 肿瘤比例评分 (TPS) 为 1%-49%，9 名 (11.3%) 的 PD-L1 TPS >= 50%；因此，35 名 (43.8%) 的 PD-L1 TPS >= 1%。在71个具有EGFR突变的肿瘤中，23个(32.4%)的PD-L1 TPS为1%-49%，7个(9.9%)的PD-L1 TPS≥50%。 >= 1%的PD-L1 TPS与所检查的任何临床特征无关。 PD-L1 TPS >= 1% 的患者初始 TKI 治疗的无进展生存率显着低于 PD-L1 TPS < 1% 的患者 (p = 0.016)。结论：EGFR 突变或 ALK 重排的患者子集的 PD-L1 TPS 为 50%。因此，有必要进行前瞻性研究来检验 PD-1/PD-L1 抑制剂对此类患者的疗效。
Objectives: Expression of programmed cell death-ligand 1 (PD-L1) has been associated with clinical outcome of programmed cell death-1 (PD-1) pathway blockade in non-small cell lung cancer (NSCLC). The PD-Ll IHC 22C3 pharmDx assay, the only companion diagnostic for pembrolizumab therapy, has revealed that similar to 30% of all NSCLCs express PD-Ll at a high level. The frequency of high PD-L1 expression in NSCLCs with known driver oncogenes has remained unclear, however.Materials and methods: We retrospectively evaluated PD-Ll expression with the 22C3 assay in tumor tissue of 80 lung adenocarcinoma patients including 71 with EGFR mutations and 9 with ALK rearrangements, all of whom were treated with corresponding tyrosine kinase inhibitors (TKIs).Results: Of the 80 tumors analyzed, 26 (32.5%) had a PD-L1 tumor proportion score (TPS) of 1%-49% and 9 (11.3%) had a PD-Ll TPS of >= 50%; 35 (43.8%) thus had a PD-L1 TPS of >= 1%. Of the 71 tumors with EGFR mutations, 23 (32.4%) had a PD-Ll TPS of 1%-49% and 7 (9.9%) had a PD-Ll TPS of >= 50%. A PD-Ll TPS of >= 1% was not associated with any clinical characteristic examined. Progression-free survival on initial TKI treatment was significantly poorer for patients with a PD-L1 TPS of >= 1% than for those with a PD-Ll TPS o f < 1% (p = .016).Conclusions: A subset of patients with EGFR mutations or ALK rearrangements had a PD-Ll TPS of 50%. Prospective studies are thus warranted to examine the efficacy of PD-1/PD-L1 inhibitors in such patients.